122 related articles for article (PubMed ID: 18482796)
1. Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo.
Wang H; Li H; Zuo M; Zhang Y; Liu H; Fang W; Chen X
Cancer Lett; 2008 Sep; 268(1):89-97. PubMed ID: 18482796
[TBL] [Abstract][Full Text] [Related]
2. Lx2-32c, a novel taxane derivative, exerts anti-resistance activity by initiating intrinsic apoptosis pathway in vitro and inhibits the growth of resistant tumor in vivo.
Zhou Q; Li Y; Jin J; Lang L; Zhu Z; Fang W; Chen X
Biol Pharm Bull; 2012; 35(12):2170-9. PubMed ID: 23207769
[TBL] [Abstract][Full Text] [Related]
3. Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells
Lv G; Sun D; Zhang J; Xie X; Wu X; Fang W; Tian J; Yan C; Wang H; Fu F
Acta Pharm Sin B; 2017 Jan; 7(1):52-58. PubMed ID: 28119808
[TBL] [Abstract][Full Text] [Related]
4. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
6. Quantitative determination of Lx2-32c, a novel taxane derivative, in rat plasma by liquid chromatography-tandem mass spectrometry.
Hu J; You F; Yang S; Li Y
J Pharm Biomed Anal; 2014 Jan; 88():483-8. PubMed ID: 24176754
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
Gallo D; Ferlini C; Distefano M; Cantelmo F; Gaggini C; Fattorossi A; Riva A; Bombardelli E; Proietti E; Mancuso S; Scambia G
Cancer Chemother Pharmacol; 2000; 45(2):127-32. PubMed ID: 10663627
[TBL] [Abstract][Full Text] [Related]
9. Lx2-32c-loaded polymeric micelles with small size for intravenous drug delivery and their inhibitory effect on tumor growth and metastasis in clinically associated 4T1 murine breast cancer.
Chen LQ; Huang W; Gao ZG; Fang WS; Jin MJ
Int J Nanomedicine; 2016; 11():5457-5472. PubMed ID: 27799769
[TBL] [Abstract][Full Text] [Related]
10. Preparation, pharmacokinetics, biodistribution, antitumor efficacy and safety of Lx2-32c-containing liposome.
Wang H; Zhang J; Lv G; Ma J; Ma P; Du G; Wang Z; Tian J; Fang W; Fu F
PLoS One; 2014; 9(12):e114688. PubMed ID: 25506928
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells.
Chen YL; Lin SZ; Chang JY; Cheng YL; Tsai NM; Chen SP; Chang WL; Harn HJ
Biochem Pharmacol; 2006 Jul; 72(3):308-19. PubMed ID: 16782069
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the structures of taxane derivatives and their microtubule polymerization activity.
Hidaka M; Koga T; Kiyota H; Horiguchi T; Shi QW; Hirose K; Uchida T
Biosci Biotechnol Biochem; 2012; 76(2):349-52. PubMed ID: 22313785
[TBL] [Abstract][Full Text] [Related]
13. FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression.
Heuer TS; Ventura R; Mordec K; Lai J; Fridlib M; Buckley D; Kemble G
EBioMedicine; 2017 Feb; 16():51-62. PubMed ID: 28159572
[TBL] [Abstract][Full Text] [Related]
14. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis.
Jordan MA; Ojima I; Rosas F; Distefano M; Wilson L; Scambia G; Ferlini C
Chem Biol; 2002 Jan; 9(1):93-101. PubMed ID: 11841942
[TBL] [Abstract][Full Text] [Related]
15. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
Cassinelli G; Lanzi C; Supino R; Pratesi G; Zuco V; Laccabue D; Cuccuru G; Bombardelli E; Zunino F
Clin Cancer Res; 2002 Aug; 8(8):2647-54. PubMed ID: 12171897
[TBL] [Abstract][Full Text] [Related]
16. Lx2-32c inhibits the formation of mammosphere from MDA-MB-231 cells and induces apoptosis involving in down-regulating FoxM1.
Cai P; Xiao Z; Pan T; Wen X; Cao J; Ouyang B
Biomed Pharmacother; 2018 Jun; 102():1176-1181. PubMed ID: 29710535
[TBL] [Abstract][Full Text] [Related]
17. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Sampath D; Discafani CM; Loganzo F; Beyer C; Liu H; Tan X; Musto S; Annable T; Gallagher P; Rios C; Greenberger LM
Mol Cancer Ther; 2003 Sep; 2(9):873-84. PubMed ID: 14555706
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
19. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.
Cassinelli G; Supino R; Perego P; Polizzi D; Lanzi C; Pratesi G; Zunino F
Int J Cancer; 2001 Jun; 92(5):738-47. PubMed ID: 11340581
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Xie CY; Xu YP; Jin W; Lou LG
Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]